Tracking economic change over a decade: an analysis of Austria's industry-sponsored clinical trial landscape and...

Industry-sponsored clinical trials (ISCTs) play a central role in pharmaceutical innovation and economic value creation. Building on a previous assessment, the aim of this study is to update the quantification of the industry-funded medical treatments and macroeconomic impact of ISCTs in Austria for 2020-2024 and to compare their development over time with the earlier observation (2012-2017), with particular attention to structural changes associated with the transition to the Clinical Trials Regulation (CTR).

The analysis followed a multi-step approach consistent with the previous assessment. ISCT activity in Austria between 2020 and 2024 was quantified, and characteristics from a representative ISCT dataset used to estimate trial duration, therapeutic distribution, and patient enrolment. The monetary value of protocol-defined medical treatments was derived using national reimbursement tariffs. Macroeconomic effects on domestic value-added and employment were estimated using an extended Leontief input-output model.

ISCTs generated an annual medical treatment value of €122.28 million (price level 2025), corresponding to €611.38 million over the five-year period, thereby relieving the Austrian healthcare system by 0.21% of annual current health expenditures. At 2025 price levels, the annual medical treatment value declined from approximately €135 million in the earlier observation period. On average, 2,314 patients were treated each year in 463 ISCTs totaling to 11,570 patients in 782 studies across the entire period (2020-2024). The total annual value-added amounted to €174.05 million, with a value-added multiplier of 1.97. ISCTs secured 2,276 full-time equivalent jobs, corresponding to an employment multiplier of 1.74; both multipliers exceeded those reported in the previous assessment and are higher than those observed in Austria's tourism sector.

ISCTs generate substantial medical and economic value in Austria. Ensuring that Austria remains in the future an attractive location for clinical research also requires sustained investment in research infrastructure and digital systems.